OneAscent Wealth Management’s Royalty Pharma RPRX Stock Holding History

OneAscent Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$332K	Buy	5,924 +63	+1%	+$3.28K	0.1%	108
2026 Q1	$281K	Sell	5,861 -2	-0%	-$88	0.09%	123
2025 Q4	$227K	Buy	+5,863	New	+$224K	0.08%	149
2025 Q3	–	Sell	-5,552	Closed	-$200K	–	189
2025 Q2	$200K	Buy	+5,552	New	+$184K	0.07%	168
2024 Q4	–	Sell	-7,458	Closed	-$211K	–	184
2024 Q3	$211K	Sell	7,458 -505	-6%	-$14K	0.08%	171
2024 Q2	$210K	Buy	+7,963	New	+$221K	0.11%	94

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OneAscent Wealth Management's RPRX Position: Q2 2026 in Review

OneAscent Wealth Management increased its Royalty Pharma (RPRX) stake by 1.1% in Q2 2026, buying an estimated $3.28K and bringing the position to 5,924 shares worth $332K. The position accounts for 0.1% of the portfolio, ranked #108.

OneAscent Wealth Management first reported a position in RPRX in Q2 2024 and has held it in 6 quarters since. 644 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

OneAscent Wealth Management held 5,924 shares of Royalty Pharma worth $332K as of Q2 2026.
OneAscent Wealth Management bought 63 Royalty Pharma shares in Q2 2026, an estimated $3.28K.
Royalty Pharma made up 0.1% of OneAscent Wealth Management's portfolio in Q2 2026, its #108 holding.
OneAscent Wealth Management first reported a position in Royalty Pharma in Q2 2024 and has held it in 6 quarters since.
644 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on OneAscent Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.